Healium

Healium operates where digital mental wellness, biofeedback, immersive technology, and clinical software overlap. Its core distinction is the conversion of wearable-derived physiological signals—including EEG, heart rate, HRV, skin conductance, and skin temperature—into real-time visual or auditory feedback, making self-regulation visible during an experience. This gives it a different emphasis from wellness products centered primarily on content or self-reported mood. The company describes use in clinical settings and deployments across hospitals, behavioral health programs, VA facilities, and Department of Defense programs; named settings include Mayo Clinic. Its research description cites 10 peer-reviewed studies, including work published in Mayo Clinic Proceedings and Frontiers in Psychology. Healium Clinical adds a supervised-care product, registered as a Class II 510(k)-exempt biofeedback device. The available company information does not identify comparable competitors by name, so a reliable competitor-by-competitor assessment or market-share comparison is not possible. Its position is therefore best understood through its specific combination of biometric feedback, immersive experiences, and institutional deployment rather than an asserted ranking against named rivals.

Healium’s funding history indicates a small-company growth path supported by a mix of seed capital and non-dilutive funding. The company raised $1.3 million in a 2019 Seed round, received $50,000 in non-equity assistance in 2020, and had an unquantified Venture Round in 2021. Its 2023 activity included a $3.6 million Seed round and a $25,000 grant, bringing reported total funding to $4.975 million across five rounds. The 2023 Seed round is the largest disclosed financing and the latest disclosed funding event is the November 2023 grant. Product and deployment milestones provide a second view of development: a Mayo Clinic-related pre-surgery anxiety use case was reported in 2025, followed by the 2026 launch of Healium Clinical and the VA in-home VR initiative with more than 700 kits described as deployed. Partnerships and deployments with SoldierPoint, Mosaic Medical Center, and Pennsylvania veterans homes suggest expansion into institutional channels. These signals show product and deployment expansion, not enough evidence to quantify revenue growth or predict its pace.